Ultralente insulin: Difference between revisions

Content deleted Content added

Inline

Revision as of 11:41, 29 March 2015

Ultralente insulin is a long acting form of insulin. It has an onset of 4 to 6 hours, a peak of 14 to 24 hours, and a duration of 28 to 36 hours.^[1] This, along with lente form of insulin, was discontinued in the US by Eli Lilly and Company in 2005. One of the reasons for discontinuation was declining use due to physicians favoring NPH insulin and other basal insulin drugs.^[2]

References

^ Gomella LG, Haist SA. Chapter 22. Commonly Used Medications. In: Gomella LG, Haist SA, eds. Clinician's Pocket Reference: The Scut Monkey. 11th ed. New York: McGraw-Hill; 2007. http://www.accessmedicine.com/content.aspx?aID=2696124. Accessed February 4, 2012
^ http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/ucm086084.pdf

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Gomella LG, Haist SA. Chapter 22. Commonly Used Medications. In: Gomella LG, Haist SA, eds. Clinician's Pocket Reference: The Scut Monkey. 11th ed. New York: McGraw-Hill; 2007. http://www.accessmedicine.com/content.aspx?aID=2696124. Accessed February 4, 2012

[2] ttp://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/ucm086084.pdf

[1]

@@ Line 4: / Line 4: @@
 {{Reflist}}
 {{Drug-stub}}
+{{Oral hypoglycemics and insulin analogs}}
 [[Category:Insulin therapies]]